NYSE:ALT - Altimmune Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.37 +0.01 (+2.78 %) (As of 07/18/2018 12:43 PM ET)Previous Close$0.40Today's Range$0.37 - $0.4052-Week Range$0.33 - $3.16Volume6,658 shsAverage Volume673,018 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. Receive ALT News and Ratings via Email Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSE:ALT CUSIPN/A Webwww.altimmune.com PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares25,800,000Market Cap$0.00 Altimmune (NYSE:ALT) Frequently Asked Questions What is Altimmune's stock symbol? Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT." How were Altimmune's earnings last quarter? Altimmune, Inc. (NYSE:ALT) issued its quarterly earnings data on Tuesday, May, 15th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.27. The company had revenue of $2.69 million for the quarter. View Altimmune's Earnings History. What is the consensus analysts' recommendation for Altimmune? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Altimmune's key competitors? Some companies that are related to Altimmune include Can-Fite Biopharma (CANF), Circassia Pharmaceuticals (CIR), Cronos Group (CRON), Devonian Health Group (GSD), Exicure (XCUR), Galena Biopharma (SLS), Immunoprecise Antibodies (IPATF), IMV (IMV), Naturally Splendid Enterprises (NSP), Novacyt (NCYT), Nuformix (NFX), Sirona Biochem (SBM) and Synthetic Biologics (SYN). Who are Altimmune's key executives? Altimmune's management team includes the folowing people: Mr. William J. Enright, Pres, CEO & Director (Age 55)Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)Dr. Sybil Tasker, Chief Medical Officer (Age 55)Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)Mr. Bertrand Georges Ph.D., Chief Technology Officer Has Altimmune been receiving favorable news coverage? Media coverage about ALT stock has trended somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Altimmune earned a media sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 44.72 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of Altimmune? Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Altimmune's stock price today? One share of ALT stock can currently be purchased for approximately $0.37. MarketBeat Community Rating for Altimmune (NYSE ALT)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 7 (Vote Outperform)Underperform Votes: 4 (Vote Underperform)Total Votes: 11MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote "Outperform" if you believe ALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?